EPRX News & Events

Eupraxia Pharmaceuticals announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the Resolve trial evaluating EP-104GI for the treatment of eosinophilic esophagitis, EoE. At 36 weeks, patients in Cohort 9 demonstrated a "robust" response in both tissue health and symptom response compared to their baseline levels. Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the Resolve trial. Clinical remission in symptoms was maintained in 66% of the patients in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks. EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase 1b/2a study and over 230 patient-months of follow-up have been reported with no drug related Serious Adverse Events. There still have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids.

Eupraxia Pharmaceuticals announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Sub-analyses of scores including at least 12 injections indicated that: at 12 weeks, 59% of patients achieved clinical remission; at 24 weeks, 76% of patients maintained clinical remission, and at 52 weeks, 67% of patients maintained clinical remission. At 24 weeks, dose cohort 9 showed a mean reduction of 4.0 points in SDI score where a reduction of 3.0 points is considered clinical remission. Comparison of histologic and symptom data from Cohort 8b versus Cohort 8 at 12 weeks demonstrated meaningfully improved outcomes due to improved drug delivery to the tissues associated with the appropriate catheter. No SAEs have been reported to date. EP-104GI has been well tolerated at all dose levels, including the highest dose of 8 mg/site.